Company intelligence / Profile preview

Enterome

Paris, Île-de-France, Franceenterome.com ↗

Ownership: Private
Employees: ~70
Development stage: Phase 2

Overview

Enterome’s lead immunotherapy candidates EO2401 and EO2463 are in Phase 2 trials for glioblastoma/adrenal tumors and indolent non-Hodgkin lymphoma respectively. Early results show promising efficacy and tolerability in over 180 patients. The company’s pipeline also includes preclinical/early clinical assets targeting IBD and food allergies through a partnership with Nestlé Health Science

Therapeutic areas: GastroenterologyOncologyImmunology
Modalities: small proteinspeptides (OncoMimics™)peptides (EndoMimics™)
Industry: Biotech

Drug pipeline

11 assets

eo2401

10 more assets in the full pipeline.

Request access →

Partnerships

Nestlé Health Science (for EndoMimic/AllerMimic development in IBD & food allergy)The Leukemia & Lymphoma Society Therapy Acceleration Program® funding partnership for EO2463

Beyond the preview

Go deeper on Enterome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterome.

Explore the full profile